February 2025 in “Clinical Cosmetic and Investigational Dermatology” This study used Mendelian randomization analysis to find a significant causal relationship between high fasting insulin levels and androgenetic alopecia, while identifying potential core genes and metabolic pathways that could mediate this link.
January 2025 in “Annals of Dermatology” This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” In this study, oral minoxidil treatment significantly increased serum VEGF levels and improved hair growth measures compared to a control group, suggesting its potential as an effective approach for promoting hair regrowth in androgenetic alopecia.
January 2025 in “Nanotechnology Reviews” This study reported a green synthesis method for copper oxide nanoparticles using pumpkin seed extract, achieving significant antibacterial activity against Bacillus subtilis and moderate cytotoxic effects against certain cancer cell lines, indicating potential biomedical applications for these eco-friendly nanomaterials.
January 2025 in “International Journal of Pharmaceutical Research and Development” This source highlights the preference for herbal-based products over chemical treatments for managing alopecia and explores their potential in hair treatment and regrowth.
December 2024 in “Varna Medical Forum” This article reviews scientific literature on the properties of essential oils and herbs in cosmetic medicine, highlighting their antimicrobial, anti-inflammatory, and antioxidant benefits in skin and hair care and their potential as natural alternatives to synthetic cosmeceutical ingredients for promoting dermatological health.
November 2024 in “Open Repository of the University of Porto (University of Porto)” This report details a six-month internship experience, split between hospital and community pharmacy settings, which enhanced practical skills and theoretical knowledge in pharmaceutical care and highlighted the pharmacist's role in ensuring safe medication use.
July 2024 in “Pharmaceutical Care España” In this case report, a 22-year-old experiencing alopecia androgénica developed low blood pressure and elevated heart rate after using an oral minoxidil and dutasteride combination, highlighting the need for careful monitoring and personalized therapy in managing medication side effects.
July 2024 in “ADMET & DMPK” This review discusses the potential for surface-modified nanostructured lipid carriers to enhance hair regrowth by improving drug absorption and stability, focusing on their use with agents like minoxidil and finasteride for hair loss treatment.
July 2024 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.
Low-dose oral minoxidil is effective and generally safe for treating hair loss in women.
June 2024 in “Bőrgyógyászati és Venerológiai Szemle” In this article, the authors review the most effective current treatments for hair loss, such as Janus Kinase Inhibitors, Platelet Rich Plasma, anti-androgens, and minoxidil, highlighting the expanding therapeutic options for alopecia.
June 2024 in “Research Square (Research Square)” This case report documented a 32-year-old man's acute pancreatitis following an overdose of finasteride, highlighting the potential for rare but severe side effects from the drug in overdose situations, and suggesting a need for further research into its safety.
In this study, 14 sessions of 675 nm laser stimulation significantly improved hair count, density, and thickness in Indian patients with androgenetic alopecia, with an increase of around 17% in hair parameters over four months.
May 2024 in “Brazilian Journal of Hair Health” This article discusses how 5-alpha-reductase inhibitors like finasteride and dutasteride are used to treat androgenetic alopecia, while highlighting the ongoing debate over their potential side effects, including sexual dysfunction and psychological issues.
May 2024 in “Brazilian Journal of Hair Health” This study reported the successful development of finasteride-loaded poly(lactic-co-glycolic acid) nanoparticles, with varying encapsulation efficiencies, aiming to enhance drug delivery for hair growth while minimizing side effects, and noted that an in vivo study will follow to assess efficacy.
This study found that mesotherapy combined with minoxidil for androgenetic alopecia shows promise with high patient satisfaction and manageable risks, though some uncommon side effects may occur.
March 2024 in “International journal of pharmaceutical sciences and drug research” In this review, the authors explored current and novel treatment options for androgenetic alopecia, noting both FDA-approved pharmacologic treatments like Minoxidil and Finasteride and various non-pharmacologic and surgical methods, including hair transplantation and scalp micro-pigmentation.
March 2024 in “Asian journal of beauty & cosmetology” In this study, Derma Genie™-H001 was shown to reduce inflammation, counteract oxidative and UVB-induced damage, and support hair growth-related gene expression in human dermal papilla cells, suggesting its potential as a functional cosmetic ingredient to alleviate hair loss symptoms.
March 2024 in “Journal of Microbiology and Biotechnology” This study suggests that phloroglucinol may enhance anagen signaling and reduce oxidative stress-induced damage in human dermal papilla cells, offering a potential therapy for hair loss.
In this study, low-dose oral minoxidil was found to have a favorable safety profile for treating alopecia, with mostly mild side effects, in both general and hypertensive populations.
December 2023 in “International Journal of Applied Pharmaceutics” This study found that 12.5% moringa seed oil demonstrated optimal anti-alopecia activity in rabbits, significantly improving hair weight compared to the treatment with 0.1% finasteride.
December 2023 in “Biointerface Research in Applied Chemistry” This study used molecular docking to identify stiripentol as a potential new inhibitor of the SRD5A2 enzyme, which is targeted for treating androgen-related diseases; however, in vivo trials are needed to validate its efficacy.
November 2023 in “Frontiers in cell and developmental biology” This source reviews mechanisms and existing treatments for hair aging, highlighting factors like oxidative stress and DNA repair defects that affect hair follicle and stem cell function, and discusses research limitations and future directions in the field.
November 2023 in “Наука і техніка сьогодні” This research provides a comprehensive comparison of hair restoration methods used in Ukraine and the USA, examining the effectiveness of surgical and non-surgical treatments for alopecia, including FUE and FUT hair transplantation, PRP therapy, and low-level laser therapy.
October 2023 in “Russian Journal of Veterinary Pathology” This source reviews existing studies on treating canine noninflammatory alopecia, identifying microneedling and oral administration of certain drugs as optimal methods with fewer side effects, while noting that other treatments like mitotane and minoxidil cause serious side effects, limiting their future use.
October 2023 in “International journal of biology, pharmacy and allied sciences” This article provides an in-depth exploration of both natural and synthetic treatments for alopecia, examining their mechanisms, benefits, limitations, and current research, while noting that synthetic therapies can have potential adverse effects.
In this study, researchers examined a document submitted by Jakeline Ortega related to Joandele Cristina da Silva Barcelos, but results or specific findings are not reported in the abstract.
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
January 2023 in “International Journal of Medicine in Developing Countries” This case report describes a 28-year-old male with androgenetic alopecia who experienced hair improvement after four months of treatment with 5% minoxidil solution.